Advertisement

Journal of Gastrointestinal Cancer

, Volume 50, Issue 3, pp 537–542 | Cite as

Clinical Significance of Serum Vascular Endothelial Growth Factor, Pigment Epithelium–Derived Factor, Tumor Necrosis Factor Alpha, and Progranulin Levels in Patients with Gastric Cancer and Gastric Precancerous Lesions

  • Evrim Kahramanoğlu AksoyEmail author
  • Muhammet Yener Akpınar
  • Özlem Doğan
  • Zeynep Göktaş
  • Ferdane Pirinççi Sapmaz
  • Gülçin Güler Şimşek
  • Metin Uzman
  • Yaşar Nazlıgül
Original Research

Abstract

Background

The purpose of this study is to evaluate serum levels of vascular endothelial growth factor (VEGF), pigment epithelium–derived factor (PEDF), tumor necrosis factor alpha (TNF-α), and progranulin in patients with gastric cancer (GC) and precancerous lesions (PCL) and to determine the usefulness of these markers as diagnostic biomarkers in these diseases.

Method

A total of 32 GC patients, 35 PCL patients, and 23 healthy controls participated in the study. The serum levels of VEGF, PEDF, TNF-α, and progranulin were measured by enzyme-linked immunosorbent assay (ELISA).

Results

The mean serum VEGF levels were 30.6 ± 12.98 pg/mL in GC, 18.2 ± 5.72 pg/mL in PCL, and 17.5 ± 5.59 pg/mL in controls. GC VEGF levels were significantly higher than both PCL and control groups (p < 0.001). The mean serum PEDF levels were 1516.1 ± 993.8 pg/mL in GC, 1039.1 ± 1002.3 pg/mL in PCL, and 767.5 ± 661.5 pg/mL in controls. The serum PEDF level in the GC group was significantly higher than that in both PCL and control groups (p = 0.004 and p = 0.038, respectively). The mean serum TNF-α levels were 46.7 ± 14.82 pg/mL in GC, 38.4 ± 11.89 pg/mL in PCL, and 33.8 ± 12.77 pg/mL in controls. There was a significant difference between GC and controls (p = 0.022) in TNF-α levels. The mean serum progranulin levels in GC were 2496.6 ± 737.8 pg/mL, 2332.0 ± 482.1 pg/mL in PCL, and 1288.7 ± 830.9 pg/mL in controls. Progranulin levels in both GC and PCL groups were significantly higher than that in the control group (p < 0.001 for both).

Conclusion

There were significant differences among patients with GC and PCL and healthy controls in terms of serum VEGF, PEDF, TNF-α, and progranulin levels.

Keywords

Gastric cancer Gastric atrophy Intestinal metaplasia VEGF PEDF TNF-α Progranulin 

Notes

Compliance with Ethical Standards

All procedures performed involving human participants were in accordance with the ethical standards of the institutional research committee (Keçiören Training and Research Hospital with reference number 01.2018/1601) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide. 2012, http://globocan.iarc. fr/Pages/fact_sheets_cancer. aspx (accessed June 20, 2016).
  2. 2.
    Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric cancer: a systematic review. Asian Pac J Cancer Prev. 2018;19(3):591–603.  https://doi.org/10.22034/APJCP.2018.19.3.591.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Arrington AK. Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World J Gastrointest Surg. 2013;5(12):321–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.PubMedGoogle Scholar
  5. 5.
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.  https://doi.org/10.1056/NEJM197111182852108.
  6. 6.
    Ding S, Lin S, Dong X, Yang X, Qu H, Huang S, et al. Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer. In Vivo. 2005;19:793–5.PubMedGoogle Scholar
  7. 7.
    Vidal O, Metges JP, Elizalde I, Valentíni M, Volant A, Molina R, et al. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg. 2009;96:1443–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med (Berl). 2007;85(1):15–22.  https://doi.org/10.1007/s00109-006-0111-z.CrossRefGoogle Scholar
  9. 9.
    Zhang Y, Han J, Yang X, Shao C, Xu Z, Cheng R, et al. Pigment epithelium-derived factor inhibits angiogenesis and growth of gastric carcinoma by down-regulation of VEGF. Oncol Rep. 2011;26(3):681–6.  https://doi.org/10.3892/or.2011.1318. CrossRefPubMedGoogle Scholar
  10. 10.
    Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology. 2001;48(40):1199–201.PubMedGoogle Scholar
  11. 11.
    Demorrow S. Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer. 2013 Jul;2(3):145–51.  https://doi.org/10.3978/j.issn.2224-4778.2013.02.02.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Linē A, Stengrēvics A, Slucka Z, Li G, Jankevics E, Rees RC. Serological identification and expression analysis of gastric cancer-associated genes. Br J Cancer. 2002;86(11):1824–30.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yang D, Li R, Wang H, Wang J, Han L, Pan L, et al. Clinical implications of progranulin in gastric cancer and its regulation via a positive feedback loop involving AKT and ERK signaling pathways. Mol Med Rep. 2017;16(6):9685–91.  https://doi.org/10.3892/mmr.2017.7796.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang XY, Wang LL, Zheng X, Meng LN, Lyu B, Jin HF. Expression of p-STAT3 and vascular endothelial growth factor in MNNG induced precancerous lesions and gastric tumors in rats. World J Gastrointest Oncol. 2016;8(3):305–13.  https://doi.org/10.4251/wjgo.v8.i3.305.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer. 2002;29(2):8.CrossRefGoogle Scholar
  16. 16.
    Yakut M, Örmeci N, Erdal H, Keskin O, Karayel Z, Tutkak H, et al. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 beta, serum toll-like receptor-4 levels and Helicobacter pylori cag A status. Clin Res Hepatol Gastroenterol. 2013;37(3):302–11.  https://doi.org/10.1016/j.clinre.2012.09.013.CrossRefPubMedGoogle Scholar
  17. 17.
    Senthilkumar C, Niranjali S, Jayanthi V, Ramesh T, Devaraj H. Molecular and histological evaluation of tumor necrosis factor-alpha expression in Helicobacter pylori-mediated gastric carcinogenesis. J Cancer Res Clin Oncol. 2011;137(4):577–83.  https://doi.org/10.1007/s00432-010-0921-9.CrossRefPubMedGoogle Scholar
  18. 18.
    Sánchez-Zauco N, Torres J, Gómez A, Camorlinga-Ponce M, Muñoz-Pérez L, Herrera-Goepfert R, et al. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. BMC Cancer. 2017;17(1):384.  https://doi.org/10.1186/s12885-017-3310-9. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Erturk K, Tastekin D, Serilmez M, Bilgin E, Bozbey HU, Vatansever S. Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. Tumour Biol. 2016;37(1):405–12.  https://doi.org/10.1007/s13277-015-3829-9.CrossRefPubMedGoogle Scholar
  20. 20.
    Loei H, Tan HT, Lim TK, Lim KH, So JB, Yeoh KG, et al. Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. J Proteome Res. 2012;11(3):1759–72.  https://doi.org/10.1021/pr201014h.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Evrim Kahramanoğlu Aksoy
    • 1
    Email author
  • Muhammet Yener Akpınar
    • 1
  • Özlem Doğan
    • 2
  • Zeynep Göktaş
    • 3
  • Ferdane Pirinççi Sapmaz
    • 1
  • Gülçin Güler Şimşek
    • 4
  • Metin Uzman
    • 1
  • Yaşar Nazlıgül
    • 1
  1. 1.Department of GastroenterologyKeçiören Training and Research HospitalAnkaraTurkey
  2. 2.Department of BiochemistryAnkara University Faculty of MedicineAnkaraTurkey
  3. 3.Department of Dietetics, Nutrition, Faculty of Health SciencesHacettepe UniversityAnkaraTurkey
  4. 4.Department of PathologyKeçiören Training and Research HospitalAnkaraTurkey

Personalised recommendations